

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of

Nobuhiko KAYAGAKI, et al

Serial No. 08/913,555

Filed: September 19, 1997

For: MONOCLONAL ANTIBODY SPECIFICALLY INTERACTING WITH Fas LIGAND AND PRODUCTION PROCESS THEREOF



Group Art Unit: 1644

Examiner: M. Tung

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D. C. 20231

Dear Sir:

Transmitted herewith is an Amendment in the above identified application.

☒ [X] No additional fee is required.☐ [x] Also attached: PTO 1449

The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	104	104	0	x \$18 =	0
Independent Claims	35	35	0	x \$78 =	0
If multiple claims newly presented, add \$260.00					
Fee for extension of time					
TOTAL FEE DUE					0

☐ [ ] Please charge my Deposit Account No. 500417 in the amount of \$. An additional copy of this transmittal sheet is submitted herewith.☒ [X] The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 500417, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

McDERMOTT, WILL &amp; EMERY

  
Robert L. Price  
Registration No. 22,685600 13th Street, N.W.  
Washington, DC 20005-3096  
(202) 756-8000 RLP:brca  
Date: January 13, 1999  
Facsimile: 202-756-8699JAN 14 1999  
GROUP 160  
65 JAN 14 PM 2:31

Docket No.: 50356-150 (715-118)

#10  
01/26/99  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :  
Nobuhiko KAYAGAKI, et al :  
Serial No. 08/913,555 : Group Art Unit: 1644  
Filed: September 19, 1997 : Examiner: M. Tung  
For: MONOCLONAL ANTIBODY SPECIFICALLY REACTING WITH Fas LIGAND  
AND PRODUCTION PROCESS THEREOF

SUPPLEMENTAL RESPONSE

Honorable Commissioner of  
Patents and Trademarks  
Washington, D. C. 20231

Sir:

Supplemental to the amendment filed November 30, 1998, and further responsive to the Official Action mailed May 28, 1998, Applicants provide the following remarks in support of the patentability of the claimed invention.

**REMARKS**

Claims 57-160 are pending in the application, while claims 1-56 were canceled without prejudice.

In the Office Action of May 28, 1998, the Examiner noted that a copy of reference number 6 (Suda et al. Cell Technology (1994) 13(8), 738-744) listed on Applicants' information disclosure statement filed September 19, 1997 was not received. For the